Fewer Lipitor promotions
Pfizer,, whose blockbuster cholesterol drug Lipitor faces increased generic competition this month, will end many promotional programs it conducted in the last six months to retain revenue from the drug.
Officials from Pfizer Inc., whose blockbuster cholesterol drug Lipitor faces increased generic competition this month, told the Wall Street Journal Wednesday that the company would discontinue many of the unusual promotional programs it conducted in the last six months to retain revenue from the drug. Pfizer, which lost exclusivity on Lipitor in late November, had offered $4 coupons and struck deals with some health plans, which the Journal reported cost the company more than $87 million. Pfizer is based in Manhattan, but has operations in the Philadelphia suburbs.
David Sell